<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111367</url>
  </required_header>
  <id_info>
    <org_study_id>GP205-1901</org_study_id>
    <nct_id>NCT04111367</nct_id>
  </id_info>
  <brief_title>Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients</brief_title>
  <official_title>A Phase IIa, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Seraprevir in Combination With Sofosbuvir in Patients With Chronic Genotype 2,3,6 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ginkgopharma CO., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ginkgopharma CO., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir
      in patients with Hepatitis C (HCV) genotype2,3,6. Efficacy was assessed by the rate of
      sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Actual End of Treatment（SVR12）</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantification (LLOQ; ie, &lt; 15 IU/mL) 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Sustained Virologic Response 4 Weeks After the Actual End of Treatment (SVR4)</measure>
    <time_frame>Posttreatment Week 4</time_frame>
    <description>SVR4 is defined as HCV RNA &lt; LLOQ at 4 weeks following the last dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Genotype 2 and 6 Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 2 and 6 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 3 Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 3 Subjects will receive oral tablets of Seraprevir 200mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seraprevir</intervention_name>
    <description>Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.</description>
    <arm_group_label>Genotype 2 and 6 Subjects</arm_group_label>
    <arm_group_label>Genotype 3 Subjects</arm_group_label>
    <other_name>GP205</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.</description>
    <arm_group_label>Genotype 2 and 6 Subjects</arm_group_label>
    <arm_group_label>Genotype 3 Subjects</arm_group_label>
    <other_name>sovaldi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Hepatitis C virus (HCV) genotype 2,3,6 infection (confirmed at screening). HCV RNA greater
        than 10,000 IU/mL at screening. Participant must be willing and able to comply with the
        protocol requirements. weight was more than 40 kg. age is between 18-75,either sex.

        Exclusion Criteria:

        Co-infection with hepatitis B virus or human immunodeficiency virus (HIV). Infection with
        HCV non-genotype 2,3,6,or Infection with mixed genotype,or Genotype cannot be confirmed.

        Medical history of major functional organ transplantation. Suffering from serious blood
        system disease(such us Thalassemia/Sickle Cell Anemia).

        Participation in a clinical study within 3 months prior to first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuegang Wu</last_name>
    <role>Study Director</role>
    <affiliation>Ginkgo Pharma Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junqi Niu</last_name>
    <phone>0431-88782013</phone>
    <email>junqiniu@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Ditan Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huichun Xing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liuzhou General Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofeng Wen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of JILIN University.</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junqi Niu</last_name>
      <phone>0431-88782013</phone>
      <email>junqiniu@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Guangxi Medical University</name>
      <address>
        <city>Guangxi</city>
        <state>Nanning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minghua Su</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

